AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32891715 — intervention group
Group type: EXPERIMENTAL
Intervention: Trifluridine/tipiracil (FTD/TPI) treatment prior to irradiation for 24 hours
Number of subjects: 4
Study 32891715 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined in vivo treatment with FTD/TPI and radiation
Number of subjects: 4
Study 32891715 — intervention group
Group type: COMPARATOR
Intervention: Capecitabine radiochemotherapy
Number of subjects: 4
Study 32892294 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive Complication Index (CCI)
Number of subjects: 1782
Study 32893266 — intervention group
Group type: EXPERIMENTAL
Intervention: Development of cardiac myxomas in CNC patients
Number of subjects: 319
Study 32893266 — intervention group
Group type: EXPERIMENTAL
Intervention: Age at diagnosis of cardiac myxomas
Number of subjects: 319
Study 32893266 — intervention group
Group type: EXPERIMENTAL
Intervention: Occurrence of myxomas by age 30
Number of subjects: 319
Study 32893266 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequency of CNC-related lesions
Number of subjects: 319
Study 32893266 — intervention group
Group type: EXPERIMENTAL
Intervention: Recurrence of myxomas
Number of subjects: 319
Study 32893266 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender differences in recurrence rates
Number of subjects: 319
Study 32893266 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk estimates for cardiac myxomas
Number of subjects: 319
Study 32893393 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg/kg dupilumab
Number of subjects: 40
Study 32893393 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg/kg dupilumab
Number of subjects: 40
Study 32893393 — intervention group
Group type: EXPERIMENTAL
Intervention: dupilumab (both doses)
Number of subjects: 40
Study 32893720 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-engaged stroke preparedness intervention
Number of subjects: 21497
Study 32894059 — intervention group
Group type: EXPERIMENTAL
Intervention: Sepsis surveillance method
Number of subjects: 1352
Study 32894059 — intervention group
Group type: COMPARATOR
Intervention: Angus' method
Number of subjects: 1352
Study 32894059 — intervention group
Group type: COMPARATOR
Intervention: Martin's method
Number of subjects: 1352
Study 32894185 — intervention group
Group type: EXPERIMENTAL
Intervention: CNCT19 CAR T therapy
Number of subjects: 22
Study 32894453 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing plus nutrition psychoeducation (MINP)
Number of subjects: 31
Study 32894453 — intervention group
Group type: COMPARATOR
Intervention: Motivational interviewing (MI) or nutrition psychoeducation interventions (separately)
Number of subjects: 31
Study 32894672 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutathione (GSH) supplementation
Number of subjects: 0
Study 32894672 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiol supplements
Number of subjects: 0
Study 32894829 — intervention group
Group type: EXPERIMENTAL
Intervention: Pivot Breath Sensor
Number of subjects: 234
Study 32894869 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantose IR test
Number of subjects: 100
Study 32894869 — intervention group
Group type: COMPARATOR
Intervention: Traditional testing methods
Number of subjects: 100
Study 32894868 — intervention group
Group type: EXPERIMENTAL
Intervention: Volatile organic compounds (VOCs) in bile
Number of subjects: 57
Study 32894868 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic regression model for VOCs
Number of subjects: 57
Study 32895005 — intervention group
Group type: EXPERIMENTAL
Intervention: Residual Synergy Between Percutaneous Coronary Intervention With Taxus and Cardiac Surgery (SYNTAX) score (RSS)
Number of subjects: 1910
Study 32895005 — intervention group
Group type: COMPARATOR
Intervention: Tertile classification of RSS (0, 1-5, and >5) and post-PCI FFR (≥0.94, 0.87-0.93, and ≤0.86)
Number of subjects: 1910
Study 32895266 — intervention group
Group type: EXPERIMENTAL
Intervention: WHO four-symptom TB screening tool
Number of subjects: 834
Study 32895266 — intervention group
Group type: EXPERIMENTAL
Intervention: Testing for TB
Number of subjects: 834
Study 32895266 — intervention group
Group type: EXPERIMENTAL
Intervention: TB test results
Number of subjects: 834
Study 32895266 — intervention group
Group type: EXPERIMENTAL
Intervention: Initiation of TB treatment
Number of subjects: 834
Study 32895266 — intervention group
Group type: EXPERIMENTAL
Intervention: CD4 count
Number of subjects: 834
Study 32895266 — intervention group
Group type: EXPERIMENTAL
Intervention: ART initiation
Number of subjects: 834
Study 32895321 — intervention group
Group type: EXPERIMENTAL
Intervention: Coiling or balloon-assisted coiling
Number of subjects: 335
Study 32895922 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroconvulsive Therapy (ECT)
Number of subjects: 65
Study 32895922 — intervention group
Group type: EXPERIMENTAL
Intervention: Montreal Cognitive Assessment (MoCA)
Number of subjects: 65
Study 32896200 — intervention group
Group type: EXPERIMENTAL
Intervention: Avatar-Facilitated Life Review Intervention
Number of subjects: 0
Study 32896211 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic cigarette (EC) vapers
Number of subjects: 33
Study 32896211 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobacco cigarette (TC) smokers
Number of subjects: 33
Study 32896211 — intervention group
Group type: COMPARATOR
Intervention: Nonsmokers
Number of subjects: 33
Study 32896301 — intervention group
Group type: EXPERIMENTAL
Intervention: Venetoclax with 10-day decitabine
Number of subjects: 168
Study 32896640 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin tape sampling technique (STS)
Number of subjects: 63
Study 32896756 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotherapy
Number of subjects: 20
Study 32896756 — intervention group
Group type: EXPERIMENTAL
Intervention: Explanatory models in psychotherapy
Number of subjects: 20
Study 32896803 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-6 levels
Number of subjects: 403
Study 32896803 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytokines and blood parameters
Number of subjects: 403
Study 32896803 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilirubin levels
Number of subjects: 403
Study 32896832 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone calls
Number of subjects: 132
Study 32896832 — intervention group
Group type: EXPERIMENTAL
Intervention: Video calls
Number of subjects: 132
Study 32896928 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 6784
Study 32897169 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI-guided transurethral ultrasound ablation (pTULSA)
Number of subjects: 10
Study 32897236 — intervention group
Group type: EXPERIMENTAL
Intervention: Biannual topical application of silver diamine fluoride
Number of subjects: 550
Study 32897236 — intervention group
Group type: COMPARATOR
Intervention: Atraumatic restorative treatment + biannual fluoride varnish
Number of subjects: 550
Study 32897402 — intervention group
Group type: EXPERIMENTAL
Intervention: NLG207 (nanoparticle-bound camptothecin)
Number of subjects: 27
Study 32897466 — intervention group
Group type: EXPERIMENTAL
Intervention: CE 3D T1-weighted fast field echo (3D T1-WI)
Number of subjects: 35
Study 32897466 — intervention group
Group type: EXPERIMENTAL
Intervention: CE 2D spin echo T1-weighted image (2D T1-WI)
Number of subjects: 35
Study 32897466 — intervention group
Group type: EXPERIMENTAL
Intervention: CE 2D T2 FLAIR
Number of subjects: 35
Study 32897466 — intervention group
Group type: COMPARATOR
Intervention: CE 2D T2 FLAIR added to CE 3D T1-WI
Number of subjects: 35
Study 32897830 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzalutamide 160 mg daily
Number of subjects: 23
Study 32898224 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram-Based Preoperative Score (NBPS)
Number of subjects: 150
Study 32898244 — intervention group
Group type: EXPERIMENTAL
Intervention: AMG 701
Number of subjects: 0
Study 32898244 — intervention group
Group type: EXPERIMENTAL
Intervention: AMG 701 + lenalidomide
Number of subjects: 0
Study 32898244 — intervention group
Group type: EXPERIMENTAL
Intervention: AMG 701 + pomalidomide
Number of subjects: 0
Study 32898244 — intervention group
Group type: COMPARATOR
Intervention: IMiDs (lenalidomide and pomalidomide)
Number of subjects: 0
Study 32898291 — intervention group
Group type: EXPERIMENTAL
Intervention: PGT-A with polar body biopsy
Number of subjects: 2794
Study 32898291 — intervention group
Group type: EXPERIMENTAL
Intervention: PGT-A with blastocyst stage biopsy
Number of subjects: 2794
Study 32898291 — intervention group
Group type: EXPERIMENTAL
Intervention: PGT-A with FISH
Number of subjects: 2794
Study 32898291 — intervention group
Group type: COMPARATOR
Intervention: IVF without PGT-A
Number of subjects: 2794
Study 32898333 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyrotinib plus SHR6390
Number of subjects: 5
Study 32898919 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized image analysis of blood vessels in the mucosal defect
Number of subjects: 86
Study 32899054 — intervention group
Group type: EXPERIMENTAL
Intervention: Tuberculin skin test (TST) performed before traveling and again 8-12 weeks after return, along with QuantiFERON-TB Gold Plus test.
Number of subjects: 492
Study 32900326 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced critical care interventions
Number of subjects: 73
Study 32900326 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age and pre-admission hypertension
Number of subjects: 73
Study 32900657 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine infusion
Number of subjects: 44
Study 32900761 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in medication purchases (painkillers and indigestion medication) 10-12 months before ovarian cancer diagnosis
Number of subjects: 1000
Study 32900761 — intervention group
Group type: COMPARATOR
Intervention: Pre-existing loyalty card data
Number of subjects: 1000
Study 32901324 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum lipase > 51 U/L on POD3
Number of subjects: 70
Study 32901324 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-6 > 56.5 ng/l on POD3
Number of subjects: 70
Study 32901324 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of serum lipase and IL-6 on POD3
Number of subjects: 70
Study 32901324 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with both or one factor(s) above cut-off
Number of subjects: 70
Study 32901324 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall and severe complications
Number of subjects: 70
Study 32902099 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Anticoagulation Therapy (OAT)
Number of subjects: 390
Study 32902182 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous bone marrow mononuclear cell transplantation
Number of subjects: 30
Study 32902182 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention based on the Early Start Denver Model
Number of subjects: 30
Study 32902182 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous bone marrow mononuclear cell transplantation combined with educational intervention
Number of subjects: 30
Study 32902200 — intervention group
Group type: COMPARATOR
Intervention: Lurasidone
Number of subjects: 1223
Study 32902200 — intervention group
Group type: COMPARATOR
Intervention: Olanzapine
Number of subjects: 1223
Study 32902200 — intervention group
Group type: COMPARATOR
Intervention: QUE-XR
Number of subjects: 1223
Study 32902390 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-mediated, pedometer-based physical activity intervention for 12 weeks
Number of subjects: 59
Study 32902391 — intervention group
Group type: EXPERIMENTAL
Intervention: Very low-carbohydrate (VLC) diet with text messages
Number of subjects: 44
Study 32902391 — intervention group
Group type: EXPERIMENTAL
Intervention: Very low-carbohydrate (VLC) diet with gifts of food and cookbooks
Number of subjects: 44
Study 32902391 — intervention group
Group type: EXPERIMENTAL
Intervention: Very low-carbohydrate (VLC) diet with urine-based ketone self-monitoring
Number of subjects: 44
Study 32902391 — intervention group
Group type: COMPARATOR
Intervention: Very low-carbohydrate (VLC) diet without enhancement strategies (control group not explicitly mentioned)
Number of subjects: 44
Study 32902743 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial Diamond-Forrester (D+F) prediction model
Number of subjects: 1440
Study 32902743 — intervention group
Group type: EXPERIMENTAL
Intervention: Updated Diamond-Forrester (D+F) prediction model
Number of subjects: 1440
Study 32902763 — intervention group
Group type: EXPERIMENTAL
Intervention: Fundal pressure
Number of subjects: 86
Study 32902763 — intervention group
Group type: COMPARATOR
Intervention: Control (spontaneous delivery without fundal pressure)
Number of subjects: 86
Study 32903033 — intervention group
Group type: EXPERIMENTAL
Intervention: STAR-guided AFD ablation
Number of subjects: 30
Study 32903033 — intervention group
Group type: COMPARATOR
Intervention: Pulmonary vein isolation
Number of subjects: 30
Study 32903035 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiopharmaceutical administrations during diagnostic nuclear medicine procedures
Number of subjects: 0
Study 32903035 — intervention group
Group type: COMPARATOR
Intervention: Standard of care scans
Number of subjects: 0
Study 32903035 — intervention group
Group type: EXPERIMENTAL
Intervention: Detailed analysis of radiation dose calculations
Number of subjects: 0
Study 32903035 — intervention group
Group type: EXPERIMENTAL
Intervention: Current risk models
Number of subjects: 0
Study 32903104 — intervention group
Group type: EXPERIMENTAL
Intervention: Office blood pressure measurement
Number of subjects: 267
Study 32903104 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-hour ambulatory blood pressure measurement
Number of subjects: 267
Study 32903104 — intervention group
Group type: EXPERIMENTAL
Intervention: Office blood pressure
Number of subjects: 267
Study 32903104 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulatory blood pressure
Number of subjects: 267
Study 32903199 — intervention group
Group type: EXPERIMENTAL
Intervention: Convalescent Plasma (CP) infusion
Number of subjects: 575
Study 32903199 — intervention group
Group type: COMPARATOR
Intervention: Matched controls (no CP due to lack of consent or availability)
Number of subjects: 575
Study 32903267 — intervention group
Group type: EXPERIMENTAL
Intervention: Karate intervention (10-week, twice weekly classes)
Number of subjects: 19
Study 32903355 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced treadmill training with real-time visualisation feedback and functional electrical stimulation
Number of subjects: 6
Study 32903355 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional electrical stimulation to pre-tibial muscles
Number of subjects: 6
Study 32903368 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological therapy
Number of subjects: 0
Study 32903368 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 0
Study 32903394 — intervention group
Group type: EXPERIMENTAL
Intervention: Dance Movement Therapy (DMT) + Treatment as Usual (TAU)
Number of subjects: 109
Study 32903394 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 109
Study 32903594 — intervention group
Group type: EXPERIMENTAL
Intervention: First-Line Treatment
Number of subjects: 0
Study 32903623 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized medicine intervention
Number of subjects: 0
Study 32903623 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 32904162 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10 mg + Ezetimibe 10 mg (R/E)
Number of subjects: 129
Study 32904162 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin 20 mg + Ezetimibe 10 mg (S/E)
Number of subjects: 129
Study 32904162 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20 mg + Ezetimibe 10 mg (R/E)
Number of subjects: 129
Study 32904162 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin 40 mg + Ezetimibe 10 mg (S/E)
Number of subjects: 129
Study 32904642 — intervention group
Group type: EXPERIMENTAL
Intervention: Electro-Acupuncture (EA)
Number of subjects: 0
Study 32904642 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual Acupuncture (MA)
Number of subjects: 0
Study 32904642 — intervention group
Group type: EXPERIMENTAL
Intervention: Both EA and MA
Number of subjects: 0
Study 32905581 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV patients with COVID-19
Number of subjects: 286
Study 32905623 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower blood pressure targets (135/85 mmHg or less)
Number of subjects: 9484
Study 32905623 — intervention group
Group type: COMPARATOR
Intervention: Standard blood pressure targets (140 to 160/90 to 100 mmHg or less)
Number of subjects: 9484
Study 32905674 — intervention group
Group type: COMPARATOR
Intervention: Recombinant factor VIII at a dose of 25 IU/kg
Number of subjects: 16
Study 32905674 — intervention group
Group type: COMPARATOR
Intervention: Recombinant factor VIII at a dose of 65 IU/kg
Number of subjects: 16
Study 32905674 — intervention group
Group type: EXPERIMENTAL
Intervention: BIVV001 at a dose of 65 IU/kg
Number of subjects: 16
Study 32905674 — intervention group
Group type: EXPERIMENTAL
Intervention: BIVV001
Number of subjects: 16
Study 32905725 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone, gabapentin, propofol, and remifentanil as part of a new clinical pathway
Number of subjects: 39
Study 32905725 — intervention group
Group type: COMPARATOR
Intervention: Control group (historically collected)
Number of subjects: 39
Study 32905959 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab 1200 mg every 3 weeks until loss of clinical benefit or unacceptable toxicity
Number of subjects: 35
Study 32905959 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Number of subjects: 35
Study 32906162 — intervention group
Group type: EXPERIMENTAL
Intervention: EN-580XP system
Number of subjects: 295
Study 32906162 — intervention group
Group type: COMPARATOR
Intervention: EN-580T system
Number of subjects: 295
Study 32907357 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine 400 mg daily during pregnancy
Number of subjects: 45
Study 32907594 — intervention group
Group type: EXPERIMENTAL
Intervention: Silent Visuomotor Cues (SVC)
Number of subjects: 10
Study 32907594 — intervention group
Group type: EXPERIMENTAL
Intervention: Semantic Auditory Cues (SAC)
Number of subjects: 10
Study 32907626 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 300 mg
Number of subjects: 40
Study 32907766 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness therapy applied to experimental group patients
Number of subjects: 112
Study 32907766 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness therapy (experimental group)
Number of subjects: 112
Study 32907766 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 112
Study 32907782 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacral neuromodulation (SNM) therapy with the InterStim™ system
Number of subjects: 320
Study 32907899 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual-level factors (e.g., walking distance to health facility, ANC visits, last birth at health facility, number of children, knowledge on FP, intentions to use FP)
Number of subjects: 891
Study 32907899 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-level factors (e.g., electronic media possession, women's decision making on FP)
Number of subjects: 891
Study 32907924 — intervention group
Group type: EXPERIMENTAL
Intervention: Avelumab 10 mg/kg intravenously every 2 weeks
Number of subjects: 156
Study 32908159 — intervention group
Group type: EXPERIMENTAL
Intervention: EDOF IOL (Tecnis Symfony IOL)
Number of subjects: 3
Study 32908159 — intervention group
Group type: EXPERIMENTAL
Intervention: Trifocal IOL (FineVision PodFT, PhysIOL)
Number of subjects: 3
Study 32908159 — intervention group
Group type: EXPERIMENTAL
Intervention: Mix-and-Match bifocal IOLs
Number of subjects: 3
Study 32908159 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 3
Study 32908559 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided percutaneous needle electrolysis (PNE) in combination with an eccentric exercise program
Number of subjects: 30
Study 32908559 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in the abstract)
Number of subjects: 30
Study 32908956 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 32909218 — intervention group
Group type: EXPERIMENTAL
Intervention: Same-day initiation (SDI) of antiretroviral therapy (ART)
Number of subjects: 593
Study 32909218 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 593
Study 32909218 — intervention group
Group type: EXPERIMENTAL
Intervention: Same-day initiation (SDI) of ART
Number of subjects: 593
Study 32909523 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavior Change Technique Taxonomy applied to childhood obesity interventions
Number of subjects: 0
Study 32909605 — intervention group
Group type: EXPERIMENTAL
Intervention: CMV-seropositivity
Number of subjects: 10122
Study 32909605 — intervention group
Group type: COMPARATOR
Intervention: Highest CMV IgG quartile
Number of subjects: 10122
Study 32909630 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel-intrauterine system (LNG-IUS)
Number of subjects: 1657
Study 32909953 — intervention group
Group type: EXPERIMENTAL
Intervention: 18F-choline PET/CT (FCH-PET)
Number of subjects: 30
Study 32909953 — intervention group
Group type: COMPARATOR
Intervention: 18F-fluorodeoxyglucose PET/CT (FDG-PET)
Number of subjects: 30
Study 32909953 — intervention group
Group type: COMPARATOR
Intervention: Whole-body MRI (WB-MRI)
Number of subjects: 30
Study 32909954 — intervention group
Group type: EXPERIMENTAL
Intervention: SmartMoms in WIC intervention (intensive 24-week behavioral intervention including nutrition education and exercise strategies, delivered through a website application)
Number of subjects: 432
Study 32909954 — intervention group
Group type: EXPERIMENTAL
Intervention: SmartMoms in WIC intervention
Number of subjects: 432
Study 32909970 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrauterine vacuum-induced hemorrhage-control device
Number of subjects: 107
Study 32910099 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose spinal cord stimulation (HD-SCS)
Number of subjects: 194
Study 32910151 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin plus pembrolizumab (45 and 75 mg/m2)
Number of subjects: 37
Study 32910151 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin plus pembrolizumab
Number of subjects: 37